Quanterix Webinar: Recent Advancements in Neurodegenerative Biomarkers: Progress Towards A Diagnostic Blood Test for Alzheimer’s Disease

Rhea-AI Summary

Quanterix Corporation (NASDAQ:QTRX) announced a webinar set for April 23, 2021, focusing on advancements in neurological biomarkers such as pTau181 and pTau217. This session will feature prominent experts including CEO Kevin Hrusovsky and Dr. Charlotte Teunissen, discussing the opportunities presented by blood plasma biomarkers in conjunction with Simoa^® technology for Alzheimer's Disease research. The event aims to highlight how these innovations can enhance clinical trials and diagnostics in the fight against Alzheimer's.

Positive

• Webinar features leading experts discussing critical advancements in Alzheimer's research.
• Focus on innovative biomarkers that could improve clinical trial outcomes.
• Simoa technology may significantly enhance precision health diagnostics.

Negative

• None.

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a webinar with leading industry experts to discuss neurological advancements related to the ultra-sensitive quantification of pTau181, pTau217, pTau231, and other neurological biomarkers. With several pharmaceutical companies making significant advances towards approval of Alzheimer's Disease therapies, this webinar discussion and live Q and A will further show the opportunity for blood plasma biomarkers combined with Simoa^® technology to help advance Alzheimer’s clinical trials and diagnostics.

The webinar will take place on Friday, April 23, 2021 at 10:00am ET. The discussion will be led by Quanterix Chairman, Chief Executive Officer, and President, Kevin Hrusovsky and will feature Charlotte Teunissen, Ph.D., UMC Amsterdam, and Henrik Zetterberg. Ph.D., University of Gothenberg.

To register for the webinar, visit https://www.quanterix.com/webinars/

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210422006053/en/

FAQ

What is the significance of the Quanterix webinar on April 23, 2021?

The webinar will feature discussions on advancements in neurological biomarkers and their potential impact on Alzheimer's research.

Who are the experts speaking at the Quanterix webinar?

The webinar will be led by Quanterix CEO Kevin Hrusovsky and include Dr. Charlotte Teunissen and Dr. Henrik Zetterberg.

How does Quanterix's Simoa technology relate to Alzheimer's research?

Simoa technology enables ultra-sensitive quantification of biomarkers, potentially enhancing clinical trials and diagnostics for Alzheimer's Disease.

What biomarkers will be discussed in the Quanterix webinar?

The webinar will discuss pTau181, pTau217, pTau231, and other neurological biomarkers.

What is the primary aim of Quanterix's technology?

The primary aim is to digitize biomarker analysis to advance precision health and improve early disease detection and treatment.